{"title": "The top 10 drugs losing US exclusivity in 2023", "author": "Fraiser Kansteiner; Eric Sagonowsky; Zoey Becker; Kevin Dunleavy; Angus Liu", "url": "https://www.fiercepharma.com/special-reports/top-10-drugs-losing-us-exclusivity-2023", "hostname": "fiercepharma.com", "description": "When AbbVie and Amgen inked their Humira patent settlement way back in 2017, it seemed way off in the distant future that the AbbVie bestseller would finally face biosimilar competition. Now, the day has come and gone. And Humira's erosion is only just starting. | The Fierce Pharma team didn't want AbbVie's Humira to have the entire patent-cliff spotlight this year, so we're presenting this special report on the top U.S. losses of exclusivity in 2023. Besides Humira, drugs from J&J, AstraZeneca and more make the list.", "sitename": "FiercePharma", "date": "2023-03-13", "cleaned_text": "Fierce Pharma Fierce Biotech Fierce Healthcare Fierce Life Sciences Events Advertise About Us Pharma Vaccines Asia Cell & Gene Therapy Drug Delivery Executives Manufacturing Facilities Recalls Warning Letters Marketing Special Reports Fierce 50 Resources Podcasts Fierce Events Industry Events Webinars Whitepapers Survey Events Subscribe Subscribe Pharma Vaccines Asia Cell & Gene Therapy Drug Delivery Executives Manufacturing Facilities Recalls Warning Letters Marketing Special Reports Fierce 50 Resources Podcasts Fierce Events Industry Events Webinars Whitepapers Survey Events Subscribe Fierce Pharma Fierce Biotech Fierce Healthcare Fierce Life Sciences Events Advertise About Us "}